Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BLUSF NASDAQ:EIDX NASDAQ:HRTX NASDAQ:IRWD NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AHRTXHeron Therapeutics$2.18-1.8%$2.04$1.04▼$3.73$338.69M1.182.16 million shs865,220 shsIRWDIronwood Pharmaceuticals$0.75-3.0%$0.69$0.53▼$7.11$125.56M0.32.55 million shs539,756 shsLGNDLigand Pharmaceuticals$121.70-2.6%$109.40$90.29▼$129.90$2.41B0.84116,807 shs106,482 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUSFBELLUS Health0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%HRTXHeron Therapeutics-1.80%+0.69%+5.83%+14.14%-28.29%IRWDIronwood Pharmaceuticals-3.04%+1.66%+4.24%-20.43%-88.35%LGNDLigand Pharmaceuticals-2.62%+6.40%+5.47%+16.72%+26.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHRTXHeron Therapeutics3.7921 of 5 stars3.50.00.04.22.71.70.6IRWDIronwood Pharmaceuticals4.5086 of 5 stars4.14.00.03.40.60.81.9LGNDLigand Pharmaceuticals4.0995 of 5 stars2.51.00.04.42.13.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUSFBELLUS Health 0.00N/AN/AN/AEIDXEidos Therapeutics 0.00N/AN/AN/AHRTXHeron Therapeutics 3.00Buy$5.00129.36% UpsideIRWDIronwood Pharmaceuticals 2.13Hold$4.78535.83% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.1720.93% UpsideCurrent Analyst Ratings BreakdownLatest LGND, IRWD, HRTX, EIDX, and BLUSF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.004/16/2025IRWDIronwood PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025IRWDIronwood PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$7.00 ➝ $1.004/15/2025IRWDIronwood PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $0.704/14/2025IRWDIronwood PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$3.00 ➝ $1.004/14/2025IRWDIronwood PharmaceuticalsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74HRTXHeron Therapeutics$144.29M2.30N/AN/A($0.22) per share-9.91IRWDIronwood Pharmaceuticals$351.41M0.35$0.05 per share15.69($1.88) per share-0.40LGNDLigand Pharmaceuticals$167.13M14.05$1.56 per share77.78$43.95 per share2.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AHRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/5/2025 (Estimated)IRWDIronwood Pharmaceuticals$880K-$0.20N/A3.01N/A-9.89%-1.87%-3.93%8/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$7.12N/A32.80N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)Latest LGND, IRWD, HRTX, EIDX, and BLUSF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025HRTXHeron Therapeutics-$0.01N/AN/AN/A$38.08 millionN/A8/5/2025Q2 2025LGNDLigand Pharmaceuticals$1.54N/AN/AN/A$43.87 millionN/A5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million5/7/2025Q1 2025IRWDIronwood Pharmaceuticals-$0.05-$0.14-$0.09-$0.23$67.02 million$41.14 million5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUSFBELLUS HealthN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUSFBELLUS HealthN/A13.8713.87EIDXEidos Therapeutics0.1411.1011.10HRTXHeron TherapeuticsN/A2.401.76IRWDIronwood PharmaceuticalsN/A3.343.34LGNDLigand PharmaceuticalsN/A5.275.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUSFBELLUS HealthN/AEIDXEidos Therapeutics31.40%HRTXHeron Therapeutics80.01%IRWDIronwood PharmaceuticalsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipBLUSFBELLUS Health24.17%EIDXEidos Therapeutics70.10%HRTXHeron Therapeutics5.86%IRWDIronwood Pharmaceuticals12.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableIRWDIronwood Pharmaceuticals220161.82 million141.27 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.94 millionOptionableLGND, IRWD, HRTX, EIDX, and BLUSF HeadlinesRecent News About These CompaniesLigand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq5 hours ago | nasdaq.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 SharesJuly 12 at 6:25 AM | insidertrades.comInsider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)July 11 at 8:14 PM | gurufocus.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in StockJuly 11 at 7:52 PM | marketbeat.comLigand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | BenzingaJuly 11 at 5:49 PM | benzinga.comLigand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMIJuly 10 at 11:40 PM | finanznachrichten.deLigand Partner Pelthos Therapeutics Launches ZELSUVMI™July 10 at 8:00 AM | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What HappenedJuly 9 at 3:33 PM | marketbeat.comBrokerages Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $146.14July 8, 2025 | americanbankingnews.comCalamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 6, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from AnalystsJuly 5, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)July 4, 2025 | marketbeat.comLigand, Pelthos Close Merger Deal With Channel's CHRO; To Launch ZELSUVMI In JulyJuly 2, 2025 | finanznachrichten.dePelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand PharmaceuticalsJuly 2, 2025 | quiverquant.comQPelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private PlacementJuly 2, 2025 | globenewswire.comLigand Announces Completion of Pelthos Therapeutics Merger with Channel TherapeuticsJuly 2, 2025 | globenewswire.comLisanti Capital Growth LLC Acquires 13,565 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 29, 2025 | marketbeat.comLGND Ligand Pharmaceuticals Incorporated - Seeking AlphaJune 26, 2025 | seekingalpha.comAndrew Reardon Sells 500 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 26, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,040.00 in StockJune 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, IRWD, HRTX, EIDX, and BLUSF Company DescriptionsBELLUS Health OTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Heron Therapeutics NASDAQ:HRTX$2.18 -0.04 (-1.80%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.18 +0.00 (+0.23%) As of 07/11/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Ironwood Pharmaceuticals NASDAQ:IRWD$0.75 -0.02 (-3.04%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.74 -0.01 (-0.97%) As of 07/11/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Ligand Pharmaceuticals NASDAQ:LGND$121.70 -3.28 (-2.62%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$121.72 +0.02 (+0.02%) As of 07/11/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
